Current Developments

  • Niclosamide is an anthelmintic drug that is a replication inhibitor against the SARS-CoV-2 virus. Recent studies have shown that Niclosamide has 40 times higher potency compared to remdesivir. Futhermore, Niclosamide had an IC50 of 0,28 µM compared with the inhibitory concentration of 500 µM attained by favipiravir

MP-204 is a best-in-class, topical product in clinical development for the treatment of viral skin infections such as anogenital warts caused by HPV, and has completed its Phase-II clinical trial.

MP 303 is a first-in-class, topical product in pre-clinical development for the treatment of non-melanoma skin cancer (“NMSC”) such as squamous cell carcinoma (“SCC”), basal cell carcinoma (“BCC”) and actinic keratosis (“AK”) through targeted necrosis and an immunomodulatory action.

MN has developed a proprietary formulation technology that can be applied to nearly all oral NSAID medications, increasing their peak plasma concentration (Cmax), shortening their time to maximum plasma concentration (Tmax) while providing gastro intestinal protection.

While having a short Tmax is preferential for a fast effect, this usually also causes a faster elimination, so the drug is only active in the therapeutic window for a shorter period of time. MN has solved this issue as well with its NSAID technology platform (“NTP”). NTP will allow for fast, long acting pain relief with diminished side effects.

The premise of the opiX technology is that it has a completely new mechanism of action that does not work through the opioid receptors and has none of the side effects associated with opioids and hence does not have an abuse potential and has been proven to be similar or stronger than high dose opioids in well established animal models.

New treatment modality for psoriasis, a chronic skin disease

 
 
 

Antibiotic Resistance & ACNE – Pre-clinical

 
 
 

MOLFAC A.I. uses custom, action specific computers to run models that learn from existing data of old molecules to produce new ones . Deep learning is a sub-field of machine learning, where models inspired by how our brain works are expressed mathematically, and are learned automatically, continuously from the data.

Deep learning is a key enabler of AI powered technologies being developed across the globe. The Company’s application of deep learning is focusing on complex models that help its custom made machine solve pharmaceutical chemistry based problems with human-like super intelligence.

 
 
 
 
 
 
1923
Prof. Mustafa Nevzat Pısak

Privately founded as Mustafa Nevzat Laboratory in Üsküdar/İstanbul by Prof. Mustafa Nevzat Pısak who played a great role in establishing contemporary pharmacy in Turkey.

 
 
 
1930

Production of Pavotin ampoule containing opium alkaloids extracted from poppy seed.

1935

An injectable product of powdered insulin was manufactured for the first time in Turkey.

1957

Moved to Mecidiyeköy/İstanbul and became a joint stock company.

1961

The first enteric-coated tablet was registered in Turkey (Entersal).

1974

Start of the production of active pharmaceutical ingredients (API).

1977

Some pharmaceutical forms such as syrups, ointments, creams and dry powder suspensions were produced at the temporary building in Yenibosna/İstanbul.

1984

A dedicated production plant established in Yenibosna to manufacture finished dosage forms of penicillin-like beta-lactams (Plant I - Penicillin-like Beta-lactam Products).

1996

A dedicated production plant established in Yenibosna to manufacture finished dosage forms of cephalosporin-like beta-lactams (Plant II - Cephalosporin-like Beta-lactam Products).

2000

The API Units were moved from İzmit-Köseköy to the new modern facilities at Çayırova-Şekerpınar. In these modern facilities, Clarithromycin and Clarithromycin granules for suspension, Sulbactam Sodium, Sultamicillin Tosylate and Sultamicillin Base were produced in those years.

2003

Yenibosna Plant III, which is one of the most modern facilities in Turkey, was completed. This plant is dedicated to non-penicillin and non-cephalosporin finished dosage forms (Plant III - Other Products).

2005

MN Pharmaceuticals signed strategic partnership agreements with several leading US generic companies for marketing and sales of its products and has submitted the first ANDA dossier to FDA. This is also a “first” for the Turkish Pharmaceutical Industry. By taking the initial step in exporting finished dosage forms to US, MN Pharmaceuticals has paved the way for the other Turkish pharmaceutical companies to follow.

2006

The API and finished dosage forms facilities have been inspected and approved by FDA in November. As a result of FDA inspection, MN Pharmaceuticals has been the first Turkish Pharma Company which has been granted the FDA approval for the API and finished dosage forms.

 
 
 
2007

The finished dosage forms facilities have been awarded the Environment Management Systems Certificate in the scope of ISO 14001 Standards by the British Management Systems Organization BSI. In May, the first export of finished dosage forms was performed from Turkey to USA.

2008

As a result of the MHRA inspection conducted in May, MN Pharmaceuticals received the Certificate of GMP Compliance of a Manufacturer from the British Ministry of Health. The second product entered the USA market in July.

2009

The newly established and the fourth production plant of the finished dosage forms facilities, Injectable Oncolytic Products Plant was completed at the beginning of 2009. Following the certification investigation studies conducted by Turkish Standards Institute, MN Pharmaceuticals Active Pharmaceutical Ingredients Plant has been awarded the Environment Management System Certificate in the scope of TSE ISO 14001 Standards in January. The finished dosage forms facilities have been awarded the OHSAS 18001 Occupational Health and Safety Certificate which was presented by the British Management Systems Organization BSI. The finished dosage forms facilities have been inspected and approved for the fourth time by German Health authorities and EU-GMP Certificate has been granted. (First approval was received in July, 2004.)

2010

2010 The Oncolytic Products Plant was approved by the US Food and Drug Administration (FDA) in May and by the European Medicine Agency (EMEA) in July. In December, the oncolytic drugs were shipped from Turkey to USA for the first time.

2011

Plant I- Penicillin like Beta lactam Products, Plant II- Cephalosporin like Beta lactam Products and Plant III- Other Products were inspected and approved by the GCC ( Gulf Cooperation Council).

2016

The MP204 completed the Phase-2 study with a 90% full recovery, the highest success rate ever recorded in the world.

2017

Artificial intelligence-based drug development platform: Molfac. Ai discovered the opiX technology.

2018

OpiX, found thanks to Molfac, has proven to be more effective than paracetamol + codeine and tramadol in animal experiments.

2020

Phase 1 study of MP404, which is a special combination with increased stomach protective feature and pain relief, has been successfully completed.

2021

Developed as an original drug therapy, Niclonex has been approved to start the Phase-3 study for the treatment of Covid 19.

2022

The international patent of MP 404 has been approved.

 
 
 
 
 
 

Team

Mehmet N. Pisak

Levent Selamoğlu

Dr. Cem Aydoğan

Kadir Karadeniz

Esat Özkan

Alper Aydın

Yalçın Sisa